Development of Apo Mimetic Peptides for the Treatment Cardiovascular Disease
$1,065,405ZIAFY2013HLNIH
National Heart, Lung, And Blood Institute
Investigators
Linked publications, trials & patents
Paper 36337032Paper 34653581Paper 34097448Paper 33800446Paper 33442570Paper 32222278Paper 31996466Paper 30863636Paper 30397748Paper 30359697Paper 29440748Paper 29141139Paper 29100061Paper 28522696Paper 28242049Paper 27879324Paper 27814978Paper 27758769Paper 26613945Paper 25634835Paper 25395590Paper 25154602Paper 24813055Paper 23985823Paper 23874769Paper 23515282Paper 23505317Paper 23325471Paper 23118226Paper 23042953Paper 22508840Paper 22427535Paper 22408624Paper 21972383Paper 21798543Paper 21672528Paper 21266551Paper 21115733Paper 20508181Paper 20484557Paper 19965776
Abstract
We previously showed that the 5A peptide can promote cholesterol efflux by the ABCA1 transporter and reduce atherosclerosis in animal models. The peptide was licensed to KineMed Inc, who received a RAID grant for performing preclinical toxicology studies, which have commenced. We have done additional structure function studies on the 5A peptide and identified 2 key hydrophobic residues in the hinge region of this bi-helical peptide for it to be able to promote cholesterol efflux. Based on this finding, we developed a new membrane solubilization model for how apolipoprotein mimetic peptides interact with membranes and promote cholesterol efflux.
View original record on NIH RePORTER →